{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:58:56Z","timestamp":1783702736805,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.euo.2020.12.007","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T22:23:06Z","timestamp":1609280586000},"page":"170-179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy"],"prefix":"10.1016","volume":"4","author":[{"given":"John P.","family":"Sfakianos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surena F.","family":"Matin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siamak","family":"Daneshmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Plimack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanta","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2020.12.007_bib0005","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2020.12.007_bib0010","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0022-5347(05)67019-X","article-title":"Upper tract urothelial neoplasms: incidence and survival during the last 2 decades","volume":"164","author":"Munoz","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0015","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.juro.2012.05.079","article-title":"Urothelial carcinoma of the bladder and the upper tract: Disparate twins","volume":"189","author":"Green","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","author":"The Cancer Genome Atlas Research Network","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.euo.2020.12.007_bib0025","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.euo.2020.12.007_bib0030","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.eururo.2015.07.039","article-title":"Genomic characterization of upper tract urothelial carcinoma","volume":"68","author":"Sfakianos","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0035","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.eururo.2017.05.048","article-title":"Comprehensive genomic characterization of upper tract urothelial carcinoma","volume":"72","author":"Moss","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0040","first-page":"300e.17","article-title":"Prospective implementation of a nonopioid protocol for patients undergoing robot-assisted radical cystectomy with extracorporeal urinary diversion","volume":"37","author":"Audenet","year":"2019","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.euo.2020.12.007_bib0045","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/1078-0432.CCR-18-2039","article-title":"Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma","volume":"25","author":"Audenet","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2020.12.007_bib0050","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1158\/1078-0432.CCR-18-3147","article-title":"Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites","volume":"25","author":"Nassar","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2020.12.007_bib0055","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.eururo.2008.06.013","article-title":"FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours","volume":"55","author":"van Oers","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0060","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2020.12.007_bib0065","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.eururo.2017.05.032","article-title":"Next-generation sequencing of nonmuscle invasive bladder cancer reveals potential biomarkers and rational therapeutic targets","volume":"72","author":"Pietzak","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0070","doi-asserted-by":"crossref","unstructured":"Hurst CD, Knowles MA. Mutational landscape of non-muscle-invasive bladder cancer. Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.urolonc.2018.10.015.","DOI":"10.1016\/j.urolonc.2018.10.015"},{"key":"10.1016\/j.euo.2020.12.007_bib0075","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/ng.2702","article-title":"An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers","volume":"45","author":"Roberts","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.euo.2020.12.007_bib0080","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive transcriptional analysis of early-stage urothelial carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.euo.2020.12.007_bib0085","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0090","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-12-0077-T","article-title":"A molecular taxonomy for urothelial carcinoma","volume":"18","author":"Sj\u00f6dahl","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2020.12.007_bib0095","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.eururo.2018.08.027","article-title":"Molecular subtypes of urothelial bladder cancer: results from a meta-cohort analysis of 2411 tumors","volume":"73","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0100","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1186\/1471-2407-14-836","article-title":"Global gene expression profiling identifies ALDH2, CCNE1 and SMAD3 as potential prognostic markers in upper tract urothelial carcinoma","volume":"14","author":"Wu","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2020.12.007_bib0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137141","article-title":"Molecular analysis of upper tract and bladder urothelial carcinoma: results from a microarray comparison","volume":"10","author":"Sanford","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.euo.2020.12.007_bib0110","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1158\/1078-0432.CCR-16-2520","article-title":"DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma","volume":"23","author":"Teo","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2020.12.007_bib0115","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","article-title":"Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma","volume":"2","author":"Liu","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2020.12.007_bib0120","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0125","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41568-019-0162-4","article-title":"Alternative tumour-specific antigens","volume":"19","author":"Smith","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euo.2020.12.007_bib0130","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2020.12.007_bib0135","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2020.12.007_bib0140","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.eururo.2018.09.022","article-title":"The cancer immunogram as a framework for personalized immunotherapy in urothelial cancer","volume":"75","author":"van Dijk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0145","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.12.007_bib0150","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2020.12.007_bib0155","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2020.12.007_bib0160","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1002\/cncr.31314","article-title":"Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA","volume":"124","author":"Agarwal","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2020.12.007_bib0165","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","article-title":"Evaluation of BGJ398, a Fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion stud","volume":"35","author":"Nogova","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.12.007_bib0170","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2020.12.007_bib0175","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"396","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2020.12.007_bib0180","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2020.12.007_bib0185","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(17)30007-4","article-title":"Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study","volume":"18","author":"Plimack","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2020.12.007_bib0190","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2020.12.007_bib0195","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.euo.2020.12.007_bib0200","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41467-017-00147-w","article-title":"Evasion of immunosurveillance by genomic alterations of PPAR\u03b3\/RXR\u03b1 in bladder cancer","volume":"8","author":"Korpal","year":"2017","journal-title":"Nat Commun"},{"issue":"15_suppl","key":"10.1016\/j.euo.2020.12.007_bib0205","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1200\/JCO.2018.36.15_suppl.4513","article-title":"Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway","volume":"36","author":"Joerger","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.12.007_bib0210","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.eururo.2015.08.034","volume":"69","author":"McConkey","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0215","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0220","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2019.02.017","article-title":"The Cancer Genome Atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability","volume":"75","author":"Kim","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0225","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What is the significance of variant histology in urothelial carcinoma?","volume":"6","author":"Lobo","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2020.12.007_bib0230","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/EDBK_175558","article-title":"New developments and challenges in rare genitourinary tumors: non-urothelial bladder cancers and squamous cell cancers of the penis","volume":"37","author":"Aragon-Ching","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.euo.2020.12.007_bib0235","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/JU.0000000000000523","article-title":"Prognostic value of variant histology in upper tract urothelial carcinoma treated with nephroureterectomy: a systematic review and meta-analysis","volume":"203","author":"Mori","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0240","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/his.13752","article-title":"Variants and new entities of bladder cancer","volume":"74","author":"Lopez-Beltran","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.euo.2020.12.007_bib0245","first-page":"444","article-title":"Molecular mechanisms of squamous differentiation in urothelial cell carcinoma: a paradigm for molecular subtyping of urothelial cell carcinoma of the bladder","volume":"33","author":"Adam","year":"2015","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.euo.2020.12.007_bib0250","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.path.2018.07.011","article-title":"Updates on the genetics and molecular subtypes of urothelial carcinoma and select variants","volume":"11","author":"Al-Ahmadie","year":"2018","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.euo.2020.12.007_bib0255","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.eururo.2018.06.047","article-title":"Targeted DNA and RNA sequencing of paired urothelial and squamous bladder cancers reveals discordant genomic and transcriptomic events and unique therapeutic implications","volume":"74","author":"Hovelson","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0260","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/ajcp\/aqz002","article-title":"PD-L1 expression reveals significant association with squamous differentiation in upper tract urothelial carcinoma","volume":"151","author":"Arriola","year":"2019","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.euo.2020.12.007_bib0265","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12885-020-06727-2","article-title":"Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation","volume":"20","author":"Morsch","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.euo.2020.12.007_bib0270","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1464-410X.2010.09900.x","article-title":"Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710)","volume":"108","author":"Scosyrev","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2020.12.007_bib0275","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1016\/j.clgc.2018.11.015","article-title":"Effects of variant histology on the oncologic outcomes of patients with upper urinary tract carcinoma after radical nephroureterectomy: a propensity score\u2013matched analysis","volume":"17","author":"Chung","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2020.12.007_bib0280","article-title":"Variant histology as a significant predictor of survival after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma","volume":"35","author":"Kim","year":"2017","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"10.1016\/j.euo.2020.12.007_bib0285","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.humpath.2018.03.015","article-title":"Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma","volume":"77","author":"Isharwal","year":"2018","journal-title":"Hum Pathol"},{"key":"10.1016\/j.euo.2020.12.007_bib0290","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2016.02.056","article-title":"Gene expression profile of the clinically aggressive micropapillary variant of bladder cancer","volume":"70","author":"Guo","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0295","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.eururo.2018.11.052","article-title":"Micropapillary urothelial carcinoma of the bladder: a systematic review and meta-analysis of disease characteristics and treatment outcomes","volume":"75","author":"Abufaraj","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0300","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.eururo.2015.01.014","article-title":"ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy","volume":"69","author":"Groenendijk","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.12.007_bib0305","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ng.3503","article-title":"Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer","volume":"48","author":"Al-Ahmadie","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.euo.2020.12.007_bib0310","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1093\/ajcp\/aqx029","article-title":"Plasmacytoid urothelial carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical analysis of 49 cases","volume":"147","author":"Fox","year":"2017","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.euo.2020.12.007_bib0315","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.juro.2012.11.084","article-title":"Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis","volume":"189","author":"Dayyani","year":"2013","journal-title":"J Urol"},{"issue":"6_suppl","key":"10.1016\/j.euo.2020.12.007_bib0320","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1200\/JCO.2018.36.6_suppl.482","article-title":"Plasmacytoid urothelial carcinoma: a clinicopathological study","volume":"36","author":"Hashemi-Sadraei","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.12.007_bib0325","first-page":"71","article-title":"Plasmacytoid urothelial carcinoma: response to chemotherapy and oncologic outcomes","volume":"6","author":"Diamantopoulos","year":"2020","journal-title":"Blood Cancer"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931120302157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931120302157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:46:43Z","timestamp":1762876003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931120302157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2588931120302157"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2020.12.007","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2020.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}